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INTRODUCTION
Neuroleptic ma lignant syndrome (NMS) is an uncommon, potentiall y le thal
complication of treatment with antipsychotic medication. First described in
America n journals by De lay and Deniker in 1968 (1), this syndrome has been
reported for many years in th e European and Japanese literature.
Neuroleptic malignant syndrome is characterized by fever, altered men tal
status, autonomic dysfunction, and generalized skeletal muscle ri gidity. Its
appearance usually fo llows use of high potency neuroleptics in th erapeu tic
doses . In the American literature, most reported cases have re sulted fr om use of
haloperidol, fluphenazine, thiothixene or piperazine deri vatives (2,3). Long-
acting depot fluphenazine has been particularly implicated (4,5). One reported
case has been attributed to thioridazine therapy (6), and another to tetrab ena-
zine and alphamethyltyrosine therapy (3).
Features of NMS are also described following use o f neuroleptics in
conj unct ion with lithium salts and tricyclic antidepressants, and in sedat ive
withdrawal syndromes (7,8). While persons of all ages may be affect ed , nearly
75 % are under age 40 , male-to-female ratio being 2: 1 (5).
CASE REPORT
A 22-year-old housewife in her eighth month of pregnancy developed
emotional labi lity which continued until the uneventful delivery of a healthy
baby boy at te rm. Following discharge from the hospital , th e patient did well
unti l three wee ks post-partum, when her husband noted that she was exhibiti ng
strange behavior. She wou ld cry unexplainably and 'speak repeatedly o n
religious themes. O n several occasions, she made telephone calls to her friends
stating that their parents had died. Her speech became increasingly incoherent
and fragmented, with perseveration of ideas. She began to neglect he r house-
work and personal hygiene, appearing self-absorbed. The patient was referred
for psychiatric evaluation and admitted to a local hospital.
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Shortly after admiss io n, th e pati ent demonst rated restlessness and psych o-
motor agitation warrant ing an intramuscul ar injection of ha loperidol, 2.5 mg.
Foll owing ad ministr atio n of the medication , she exh ib ited robot-like move-
ments , muscular rigidity, and oculogyri c cr isis. Also noted were hypo kinesia ,
psychomotor retardation , drowsin ess, and tongue protrusion . T reatment with
haloperidol, 2 mg daily, was continued. On th e eigh th hosp ita l day, th e patient
became unresponsive and incont inent of urine and feces. By hosp ital da y ten , she
required co ntinuous nursing ca re. Intravenous fluids were administered and
haloperidol was discontinued. Within two days, the pat ien t became more
responsive and was able to reco gnize her spouse .
Twel ve days after ad m issio n to her loca l hosp ital , the patient was trans-
fe rred to our faci lity. Ph ysical exami na tion noted an indwelling urinary cathe-
ter, large bli sters o n both heels, a protruding tongue with hypersali vat io n , and
athetoid movements of the upper ex tremit ies . T he fo llowi ng day, the patient
showed increasing agitation, and thiothixen e , 40 mg ora lly, was given . Within
24 hours, she was noted to be diaphoreti c and tach ycard ic. A ll neuroleptic
medications were di scontinu ed , and in th e ensu ing fo ur days she improved . O n
th e ninth hospital day, because of her inc reasing para noia and accompanying
agita tio n, the pati ent was given a dose of haloperidol , 10 mg in tramuscularly.
Within 24 hours, she developed extreme muscular rigidi ty, di aphoresis, tach y-
card ia, and hypersali vation. Her mental sta tus became increasingly stuporous
and the foll owing day she developed hyperthe rmia (38 .6°C, 10 1.5°F), wh ich
lasted for approx ima tely two days. A slow recove ry fo llowed with the di scont in-
uation of a ll neuroleptic medication . She was di sch arged after 16 days in the
hospital with no persistent sid e-effects.
CLIN IC AL CHARACTERISTICS
Classica lly, N MS is ch aract erized by th e tr iad of muscul ar r igidity, hyper-
th ermia , and altered co nsciousness (9). Recent descriptions a lso include auto-
nomic dysfuncti on (2 ,10) . Symptoms usuall y begin soon afte r starting or increas-
ing the dosage of ne uroleptics . O nset of the syndrome may occur within hours,
or ma y be de layed fo r severa l months fo llowi ng in itial drug exposure. So me
NMS patien ts have reported p revious asymptomatic ex posure to neuroleptics: in
other cases neuroleptics ha ve been resta rted without recurren ce of NMS after
th e ac ute syndrome is resol ved (2).
It is not clear why suc h var iations ex ist. Perhaps neuroleptics may be
necessary but are no t in th emsel ves suffic ient to induce the syndrome. Itoh (10)
noted th at physical ex ha ust ion associate d with dehydration was an underlying
co nd it ion of NMS in all 14 pati ents studied, suggesting th at dehydrat ed and
debilitated sta tes may at least predispose or contr ibute to onset of NMS. In our
patient , th e post-partum sta te was present.
Among th e earliest sig ns of MS are extrapyramidal rigidity and in volun-
tary movements, some times accompanied by dysa r th r ia and d ysphagia . H yper-
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thermia, appearing after the extrapyramidal signs, may reach 41 0 C (10 5 0 F), or
may be only moderately elevated (2). Consciousness is altered and can appear as
a dazed mutism (similar to catatonia) with subsequent progression to stupor,
coma, and death (2).
Autonomic dysfunction includes pallor, diaphoresis, sialorrhea , blood pres-
sure instability, tachycardia, pulmonary congestion, and tachypnea . In some
cases, tachypneic hypoventilation from decreased chest wall compliance necessi-
tates respiratory support. Dehydration is common and ma y progress to acute
renal failure in the absence of myoglobinuria. Less frequent signs are ocul ogyric
crisis , opisthotonus, seizures, chorea, Babinski signs, and trismus.
Symptoms usually resolve within five to ten days after stoppi ng oral
neuroleptics but last for several weeks after long-acting depot inj ection s. In 16%
to 30 % of cases fatalities have occurred from acute renal failure , respi rat o ry
failure, or cardiovascular collapse (2). Death has been more common among
those who receive depot fluphenazine, probably because of its prolonged
half-life. Postmortem examinations of the central nervous system have revea led
no consistent abnormalities.
Laboratory findings frequently are normal. Transient elevati on of serum
aldolase or creatinine phosphokinase (CPK) has been repeatedly observed .
Laboratory concomitants of dehydration can be seen , and liver paren ch ymal
enzyme elevations have been noted. Leukocytosis with a polymorphonuclear cell
predominance is com mon without other evidence of infecti on . T he sedimenta-
tion rate ma y be e levated . Cerebrospinal fluid is normal , as is th e co mputerized
tomography scan . The electroencephalogram ma y be normal or nonspecifica lly
slow, suggesting diffuse metabolic encephalopathy.
DIFFERENTIAL DIAGNOSIS
Hyperthermia and altered mental status are card ina l signs of C NS infec-
tions, therefore, NMS is most often mistaken for an infection. Bact erial, fungal
and parasitic infections, viral or syphilitic encephalitis, and even tetanus must be
ruled out in the differential diagnosis . Occasionally, trauma or neoplasms can
produce akinetic mutism and hyperthermia of a central o r igin which a lso
resembles NMS.
Drug allergy should be considered. One must look for eos inoph ilia and
cutaneous abnormalities suc h as erythema or rash. H ypertonicity in NMS is
similar to extrapyramidal rigidity and must be differentiated from basal ganglia
diseases such as severe Parkinson 's di sease. Other disorders of muscle hyperto-
nicity such as decerebrate and decorticate rigidity, tetany, and spasticit y must be
ruled out.
Catatonia ma y resemble NMS. The classic signs of ca ta to n ia, inclu d ing
ca ta lepsy and wax y flexibility, negativism, mutism , muscular r igidity, and
bizarre mannerisms can be present in MS (11). Catatonia is a no nspecific
descriptive syndrome which can result from metabolic, infectious, psychi at r ic,
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or structural brain disorders. In " le tha l catatonia," sus ta ined agi tation pro-
gresses to withdrawal, stupor (12,13), hypotension , hyperthermia , and death in
days to weeks.
If the patient has been exposed to a hot environment, heat st roke should be
considered, especially if anticholinergic drugs have been give n as they can
inhibit sweat ing . In heat stroke, as in NMS, hyperpyrexia and a depressed level
of consciousness occur, but extrapyramidal signs prior to temperature e levation
are lacking.
Finally, malignant hyperthermia (MH) must be co nsidered in that hyper-
thermia, rigidity, and CPK elevation occur in both syndromes, and they may
have a co mmo n pathophysiology (2 , 12, 14) . In about one-third of the cases of
MH, predisposition is transmitted as an autosomal dominant trait; familial MS
has not been reported. Serum CPK, which is markedly elevat ed duri ng MH, may
also be increased in patients between attacks or among asymptomatic family
members. Most patients with NMS have normal serum CPK before and after
each episode. Mortality from MH approaches 70 %, whereas among cases of
NMS it is less than 30 %.
PATHOGENESIS
T he exact pathogenesis of NMS remains unclear. A popular hypothesis
suggests a peripheral mechanism, mainly because of th e clinical similarities
between NMS and anesthetic-induced malignant hyperthermia (15). Studies
have indicated that MH may result from excessive release of ca lcium into
ske le tal muscle cytoplasm due to altered membrane transport of ca lcium in the
presence of cer ta in drugs (15) . Excess intracellular ca lcium co uld cause the
rigidity and the subsequent hyperpyr exia seen in both MH and N MS.
Some autho rs (2, 12 ,16) ha ve postulated th at th e disturbance of N MS is pri-
marily ce ntra l, suggesting that dopamine receptor blockade o r dopamine deple-
tion in th e ba sal ganglia , hypothalamus, o r brain stem is th e mai n pathophysio-
logi c mechanism. Impaired th ermoregulation by neuroleptic d r ugs which block
dopamine receptors, is seen both clinicall y and ex per imenta lly. Dopamine and
related neurotransmitters are fo u nd in th e hypothalamus, and dopam ine recep-
tors of th e 0-1 class, whi ch mediate th ermoregulation , a re locat ed in the
preoptic anterior hypothalamus. The mesolimbic dopaminergic path ways may
also playa role in th ermoregulation .
H yperpyrexia can result from elevat ion of the hypothalamic "set-point,"
impaired heat di ssipation mechanisms, or excess heat product ion . Because
patients with NMS swea t profusely, some peripheral routes of heat dissipation
are intact. However, vasoconstr ictio n is seen in neuroleptic-treated animals
made hyperthermic, and pallor in N MS patients sug ges ts that th ere is peripheral
vasocons tr ictio n which prevents heat transfer fr om th e body core to the
environment. A considerable amount o f heat is generated by th e profound
rigidity and tremors seen in NMS. These extrapyramidal signs precede , and
probably co ntr ib ute to, the hyperpyrexia.
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To achieve results in treating NMS, symptoms must be recognized early and
all psychotropic medications must be promptly withdrawn. Until recently,
medical treatment of NMS was limited to symp toma tic th erapy with intensive
supportive medica l care, with particular attention to maintenance of res p irato-
ry, renal , and cardiovascular systems. Vigorous treatment of hyperthe r mia as
we ll as maintaining fluid and electrolyte balance has also been important.
Recent reports describe successful pharmacologic treatment of NMS usin g
dantrolene sodium (17,18,19) . Dantrolene, a direct-acting skeleta l m uscle relax-
ant with unclear central effects , has been shown to be efficac io us in trea tin g
ma lignant hyperthermia in animals and humans. In muscles, it di ssociates
excitation-contraction coupling by inhibiting the release of ca lcium ions fr om
the sarcoplasmic reticulum (SR) through actions on th e tran sverse tubular
membrane-S R coupling, on SR directly, or both (20). Dosages of 50 mg orally
taken two to four times daily have resulted in rapid clinical improvement and
shortened the duration of NMS from the usual five to ten days to less th an three
days. Further use of this agent in NMS patients is warranted to dete rmine its
efficacy, optimal dosage, and route of administration. Other pharmacologic
therapies have been aimed at directl y altering the CNS dopaminergic/ ch oline r-
gic ratio through administration of anti-Parkinsonian age nts. McCarron et a l.
(21) and Amdurski et al. (22) recently reported success fu lly treating NMS with
amantadine. Bromocrip tine has also been tried (23).
SUMMARY
Neuroleptic ma lignant syndrome is a rare but underreco gnized co mplica-
t ion of neuroleptic therapy characterized by generalized ske leta l muscle r igidi ty,
hyperthermia, autonomic dysfunction , and a ltered consciousness. Recogn ition
of NMS and immediate withdrawal of neuroleptics usually leads to co mplete
recovery. Fail ure to recognize this synd rome can increase th e risk of morbidity
and ma y lead to death in a significant percentage of patients. T he pathogenesis
of NMS remains unknown, but both peripheral and central mech anisms ha ve
been proposed. Based on these hypotheses, there have been reports of successful
treatment using dantrolene sodium, a peripheral muscle relaxant and ce ntra lly-
act ing agents such as amantad ine. Further stud ies are needed to elucidate the
cause and optimal treatment of this syndrome.
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